Results 111 to 120 of about 191,868 (197)

Pragmatic cancer approach − time to change?

4 open, 2018
Tez Mesut
doaj   +1 more source

Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR. [PDF]

Sci Prog
Cholon DM, Aleksandrov LA, Quinney NL, Boyles SE, Jensen TJ, Aleksandrov AA, Gentzsch M.   +6 more
europepmc   +1 more source

Metatranscriptomic analyses of gut bacterial and viral communities in the critically endangered Yangtze finless porpoise (Neophocaena asiaeorientalis asiaeorientalis) under distinct environments. [PDF]

Anim Microbiome
Fan S, Liu H, Yan Y, Xu M, Wan X, Hao Y, Gong C, Wang C, Zhang Y, Liu D, Zheng J, Chen J.   +11 more
europepmc   +1 more source

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR. [PDF]

Front Pharmacol
Pranke I, Capurro V, Chevalier B, Pesce E, Tomati V, Pastorino C, Kelly-Aubert M, Hatton A, Dreano E, Lena M, Bocciardi R, Zara F, Pantano S, Terlizzi V, Lucanto C, Costa S, Claut L, Daccò V, Poli P, Maschio M, Fabrizzi B, Caporelli N, Cipolli M, Volpi S, Chedevergne F, Cosson L, Macey J, Ramel S, Weiss L, Grenet D, Le Clainche-Viala L, Douvry B, Ravoninjatovo B, Audousset C, Tatopoulos A, Richaud-Thiriez B, Baravalle M, Thouvenin G, Labbé G, Mittaine M, Reix P, Durieu I, Mankikian J, Bui S, Nguyen-Khoa T, Khoukh K, Martin C, Da Silva J, De Carli P, Castellani C, Cresta F, Galietta L, Guillemaut A, Girodon E, Remus N, Bulcaen M, Ensinck M, Zajac M, Carlon M, LeBihan J, Burgel PR, Sermet-Gaudelus I, Hinzpeter A, Pedemonte N.   +63 more
europepmc   +1 more source

Mesenteric Fibromatosis Presenting As Acute Abdominal Pain Mimicking a Perforated Viscus: A Case Report. [PDF]

Cureus
Kostara K, Tez M, Velazquez B, Liguori T, Kostaras V.   +4 more
europepmc   +1 more source

Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. [PDF]

Eur Respir J
Mall MA, Wainwright CE, Legg J, Chilvers M, Gartner S, Dittrich AM, Stehling F, Conner S, Grant S, Suresh N, Weinstock TG, Davies JC, VX20-445-119 Study Group.   +12 more
europepmc   +1 more source

Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]

Am J Respir Crit Care Med
Wilson G, Hughes D.
europepmc   +1 more source

Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis. [PDF]

Pulm Ther
Rubin JL, McKinnon C, Pedra GG, Morgan DA, Zweig K, Liou TG.   +5 more
europepmc   +1 more source

Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis. [PDF]

World J Clin Oncol
Tez M.
europepmc   +1 more source

Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review. [PDF]

Clin Pharmacokinet
Elzinga FA, Malik PRV, Akkerman OW, Rottier BL, van der Vaart H, Touw DJ, Koppelman GH, Mian P.   +7 more
europepmc   +1 more source